Safe & Efficient Management of Novel Oral Anticoagulants (NOACs)/Direct Oral Anticoagulants (DOACs)
The Novel / Direct Oral Anticoagulant modules from 4S DAWN enable you to safely and efficiently manage your patients on either Dabigatran, Rivaroxaban or Apixaban ensuring safe prescribing and follow-up of patients.
Structured questionnaires for initiation and follow-up are utilised, covering age, INR preconditions, comorbidities, contraindicated and interacting drugs, creatinine clearance calculation, compliance and adverse events, among others.
- Enable protocol driven care
- Ensure all information is in one place
- Track adherence and patient feedback
- Track side-effects and bleeding/thrombosis
- Improve consistency of dosing practices
- Increase patient safety and reduce clinical risk
- Increase productivity and efficiency gains
All information captured in the questionnaires is closely integrated with the patient’s overall treatment plan and a history of all treatment plans along with cessation reasons is provided with lists available to follow-up and track patients.
Novel / Direct Oral Anticoagulant – Dabigatran
The DAWN AC Dabigatran (Pradaxa®) Module provides structured questionnaires based on the recommended use of the anticoagulant and include Initiation and Routine Follow-up. Completion of the questionnaires can be scheduled for future dates so that the user can keep track of patients who have started on Dabigatran or are due for a change to Dabigatran.
Watch a demonstration of the Dabigatran Module
View the Boehringer Ingelheim Official Site for Dabigatran (Pradaxa®)
Novel / Direct Oral Anticoagulant – Rivaroxaban
The DAWN AC Rivaroxaban (Xarelto®) Module is designed for patients treated for AF, DVT and PE, and enables you to manage patients using specific forms set up as questionnaires which are incorporated into the patients overall treatment. Key questionnaires include: age; INR; comorbidities; interacting concomitant medication; renal function; CHADS2; induction and follow up.
Watch a demonstration of the Rivaroxaban Module
View the Bayer Healthcare Plc. official site for Rivaroxaban (Xarelto®)
Novel / Direct Oral Anticoagulant – Apixaban
The Apixaban (Eliquis®) Module is designed for patients treated for AF, DVT, PE, and Hip/Knee indications and enables you to manage patients using specific forms set up as questionnaires which are incorporated into the patient’s overall treatment plan. Initiation and follow-up questionnaires include: age; INR; comorbidities; interacting concomitant medication; renal function; and CHA2DS2VASC.
COMING SOON – Apixaban Module
View the BMS / Pfizer official site for Apixaban (Eliquis®)
COMING SOON – Edoxaban Module
View the Daiichi Sankyo official site for Edoxaban (Lixiana®)